Learn
Delve into dermatology diseases with new approaches from conventional to complementary care.
Topics
Explore a broad spectrum of dermatological conditions and topics to enhance your practice.
Training Programs
Expert led instruction for every level of patient care.
Log in to see enrolled program content.
Conferences
Gain practical insights and meet new colleagues.
Hover over a conference to view recordings.
Join Us
The largest integrative dermatology community.
Jason Ezra Hawkes
, MD MS FAADBiography
Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, Oregon. He completed his medical school and residency at the University of Utah. During medical school, he completed a fellowship in translational immunology in the NIH-HHMI Research Scholars Program. He also received a Master’s Degree in Clinical Investigation from Rockefeller University, where he was Chief Clinical Scholar and Principal and sub-Investigator on multiple human research protocols in the Laboratory for Investigative Dermatology. He has held academic appointments in the Departments of Dermatology at the University of Utah, University of California-Davis, Icahn School of Medicine at Mount Sinai.
Dr. Hawkes is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee. He also serves as the official delegate of the AAD as a member of the international guidelines and workgroup committee for urticaria. His research has been funded by the NIH, NSF, NPF, and Dermatology Foundation, and he is the recipient of several teaching awards including NPF Outstanding Educator in Psoriatic Disease and Exceptional Teacher of the Year in the Department of Dermatology at Mount Sinai. His primary clinical and research interests include novel immune therapies for inflammatory conditions like psoriasis, atopic dermatitis, HS, alopecia areata, vitiligo, and urticaria.
Related Content
The Science of Psoriatic Disease: A Foundation for the Clinic
Psoriasis is a complex, heterogeneous inflammatory disease characterized by thickened, red, scaly plaques and systemic inflammation that include the joints and the cardiovascular system. Multiple signaling pathways appear to modulate this inflammatory disease with development of efficacious topical, oral, and injectable therapies. This lecture will summarize the role of IL-17/23, the JAK and TYK2 pathway, phosphodiesterase 4 receptor, aryl hydrocarbon receptor, retinoid receptors, vitamin D receptors, calcineurin inhibitors, and steroids in the modulation of psoriasis.
Managing a Patient with Chronic Plaque Psoriasis that is Recalcitrant to Multiple Therapies
Review case management skills in this case-based microlearning course featuring a patient with chronic plaque psoriasis.
Case-Based Learning: Difficult Psoriasis – Challenges from the Clinic
This webinar will review complex cases of psoriasis and psoriatic arthritis and discuss the clinical approach to diagnosis, selection of therapy, and comprehensive long-term management of the disease and overall patient care.
2024 Integrative Dermatology Symposium Lectures
Do you have patients who would like to turn back the clock? You're not alone! The field of age management is skyrocketing. With so much new information, it's hard to know fact from fiction. The 2024 Integrative Dermatology Symposium focused on evidence-based science in aging and wellness, drawing insights from conventional and integrative medicine. Watch or revisit the conference recordings and delve into what can enhance patients' youthful and healthy appearance and, more importantly, what can make them feel it too.
IDS 2024 Evaluation Form
The annual Integrative Dermatology Symposium is designed to appeal to practitioners across disciplines. It will address emerging trends, and practical approaches to dermatology as practitioners assess and manage skin conditions and care. It is estimated that nearly one-third of the population is afflicted with a skin disorder. There is a great need for best practice sharing and cross-collaboration to support practitioners in the field and improve patient care outcomes.
Unraveling the Mystery: The Role of Type 2 Inflammation Across AD, PN, CSU, and BP
Join experts Raj Chovatiya, MD, PhD, MSCI; Jason Hawkes, MD, MS; and Erin Barrett, MD, at the educational ADVENT LearnSkin 2025 Cross-Dermatology Webinar, where they will explore the clinical similarities and differences among AD, PN, CSU, and BP. The discussion will highlight the significance of type 2 inflammation as a common thread in the signs and symptoms of these conditions, as well as the shared and unique inflammatory pathways underlying their pathophysiology.
Extracutaneous Comorbidities of Psoriasis: Joint, Cardiovascular, Metabolic, and Psychological Impact
Psoriasis is a complex condition that can affect the body beyond the skin, including influences on joint, cardiovascular, metabolic, and psychological health. This lecture will outline the pathophysiology and diagnostic criteria for psoriatic arthritis, cardiovascular inflammation, and the co-morbidities associated with gut and psychological health.
Emerging Topical Treatments for Psoriasis
While topical steroids are widely used for mild to moderate psoriasis, several new nonsteroidal medications have emerged with recent FDA approvals. Topical approaches for treating itch and inflammation will be discussed.
Clinical Case Discussions in Psoriasis and Psoriatic Arthritis
Challenging clinical cases of psoriasis and psoriatic arthritis will be discussed along with a discussion of how to approach topical therapy and when to consider systemic treatments.
Psoriasis Treatment for Pediatric Patients, Pregnancy, and Special Sites
This lecture will provide an overview of clinical data regarding the safe and effective use of topical, systemic, and biologic psoriasis therapies in children, during pregnancy, and for special or difficult to treat body sites such as the face, scalp, skin folds, hands/feet, and genitals.
The Use of Systemic Medications in Psoriasis and Psoriatic Arthritis
Many systemic therapies are now available for use in psoriasis and psoriatic arthritis and include the use of biologics and oral medications. This includes specific targeting of TNF and the IL-17/IL-23 pathways as well as the emergence of oral JAK and TYK2 inhibitors. The role of phototherapy will be discussed.
Master Class
Comprehensive Management of Psoriasis and Psoriatic Arthritis in Adults and Children
Comprehensive Management of Psoriasis and Psoriatic Arthritis in Adults and Children
